Pluripotent stem cell‐based screening identifies CUDC‐907 as an effective compound for restoring the in vitro phenotype of Nakajo‐Nishimura syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Stem Cells Translational Medicine"
DOI: 10.1002/sctm.20-0198
Abstract: Nakajo‐Nishimura syndrome (NNS) is an autoinflammatory disorder caused by a homozygous mutations in the PSMB8 gene. The administration of systemic corticosteroids is partially effective, but continuous treatment causes severe side effects. We previously established a… read more here.
Keywords: nishimura syndrome; nakajo nishimura; stem cell; cudc 907 ... See more keywords
CUDC-907 Promotes Bone Marrow Adipocytic Differentiation Through Inhibition of Histone Deacetylase and Regulation of Cell Cycle.
Sign Up to like & getrecommendations! Published in 2017 at "Stem cells and development"
DOI: 10.1089/scd.2016.0183
Abstract: The role of bone marrow adipocytes (BMAs) in overall energy metabolism and their effects on bone mass are currently areas of intensive investigation. BMAs differentiate from bone marrow stromal cells (BMSCs); however, the molecular mechanisms… read more here.
Keywords: cell cycle; adipocytic differentiation; differentiation; cudc 907 ... See more keywords
The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-123793
Abstract: Introduction FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations are found in approximately one quarter of acute myeloid leukemia (AML) cases. Its presence results in constitutive activation of the FLT3 receptor tyrosine kinase and… read more here.
Keywords: combination; gilteritinib; cudc 907; flt3 itd ... See more keywords
CUDC‑907 suppresses epithelial‑mesenchymal transition, migration and invasion in a 3D spheroid model of bladder cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Oncology reports"
DOI: 10.3892/or.2023.8567
Abstract: CUDC‑907 is a novel inhibitor of phosphoinositide 3‑kinase and histone deacetylase. It exerts anticancer activities by inducing apoptosis and inhibiting the growth and metastases of various tumors. However, the anticancer effects of CUDC‑907 on bladder… read more here.
Keywords: migration invasion; bladder cancer; bladder; cudc 907 ... See more keywords